At present, four types of chimeric antigen receptor T-cell (CAR-T) therapy are FDA approved for specific types of lymphoma: for relapsed or refractory (R/R) mantle cell lymphoma, brexucabtagene autoleucel, for R/R follicular lymphoma, axicabtagene ciloleucel, and for some aggressive forms of non-Hodgkin lymphoma, axicabtagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel. Despite these approvals, progression of disease and toxicity remain unresolved concerns associated with CAR-T therapy which are currently being investigated.
In this podcast, Caron Jacobson of the Dana-Farber Cancer Institute, Boston, MA, Stephen Schuster of the Perelman School of Medicine, Philadelphia, PA, Jeremy Abramson of the Massachusetts General Hospital Cancer Center, Boston, MA, Frederick Locke of the H. Lee Moffitt Cancer & Research Institute, Tampa, FL, David Miklos of Stanford University, Stanford, CA, Mazyar Shadman of the Fred Hutchinson Cancer Research Center, Seattle, WA, and Sonali Smith of the University of Chicago, Chicago, IL, discuss the latest updates on CAR-T therapy for the treatment of lymphoma.
The current status of CAR-T therapy in CLL and challenges in this space
Managing and treating GvHD and other post-transplant complications
The role of MRD in multiple myeloma
Novel immune therapies in MDS and challenges in this space
NHL highlights at ASH 2022: Updates in MCL, the role of transplantation, and novel bispecific antibodies
MPN highlights at ASH 2022: Novel agents, combinations & the role of immunotherapy
T-cell lymphoma highlights at ASH 2022: Unmet needs, clinical trial updates & future outlooks
The importance of CD47 in MDS and other targets of interest
CLL highlights at ASH 2022: Clinical trial updates, novel BTK inhibitors & combination therapy
Myeloma highlights at ASH 2022: Improving access to CAR-T therapy & future outlooks
Highlights in MDS at ASH 2022: Treating lower-risk & higher-risk disease, trial updates, & more
iwNHL Session V: Novel therapies in NHL - the role of ADCs
iwAL 2022 Session V: Mechanisms of resistance to targeted therapies in AML
The importance of genomic testing in CLL and its role in clinical decision-making
iwNHL Session IV: T-cell therapies for NHL: CAR-T therapies & third-party EBV T-cells
Key updates in CLL: novel treatment strategies, the changing role of chemotherapy, and more
iwAL 2022 Session IV: The evolving treatment landscape in ALL and the growing role of immunotherapies
iwNHL Session III: Exploring the optimal management of R/R follicular lymphoma in an expanding treatment landscape
iwAL 2022 Session III: Novel targets, combinations and treatment strategies in AML
Recent updates in CML: treatment strategies, clinical trials, and novel agents
Create your
podcast in
minutes
It is Free
Good Mood Revolution
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
Precision Medicine Forum Podcast
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive